![](/img/cover-not-exists.png)
A prospective, observational safety study of patients with BRAF V600 -mutated unresectable or metastatic melanoma treated with vemurafenib [Zelboraf Safety Study (ZeSS)]
Corrie, P.G., Terheyden, P., Ten Tije, A.J., Herbst, R., Jansen, R., Marples, M., Debus, D., Marconcini, R., Blasinska-Morawiec, M., Freivogel, K., Munson, M.L.G., Goodman, G.R., Hsu, J.J., Sadetsky,Language:
english
Journal:
British Journal of Dermatology
DOI:
10.1111/bjd.17465
Date:
November, 2018
File:
PDF, 233 KB
english, 2018